When somatic mutations are associated with a higher aggressive behavior—a story of announced evidence
Menée à partir de l'analyse génomique d'échantillons tumoraux prélevés sur 1 051 patients atteints d'un cancer papillaire de la thyroïde traité entre 1990 et 2015 (âge médian : 46 ans ; 764 femmes et 287 hommes ; durée médiane de suivi : 89 mois), cette étude évalue l'association entre la coexistence de mutations V600E du gène BRAF et de mutations du promoteur TERT, et la mortalité spécifique
We read with interest the article by Liu et al1 concerning the prognostic value of the genetic duet of coexisting BRAF V600E and TERT promoter mutations in papillary thyroid cancer (PTC)-related mortality. We found some points in common on this challenging topic. According to the literature, the active debate concerning the diagnostic and prognostic role of somatic mutations and rearrangements, such as BRAF V600E, RET/PTC, or RAS mutations in PTC, has not been resolved.1,2 In fact, studies by Fugazzola et al3 and Puxeddu et al4 did not assess any significant association of BRAF V600E mutation with any of the common high-risk pathological characteristics and implication to the disease-free survival. However, in most of these series, the number of the cases examined was much smaller, ranging from 56 to 60, and several of them were conducted without subtype stratification of PTCs. This latter point might affect the percentage of genetic alteration because BRAF V600E mutation occurs mostly in conventional and tall-cell PTC and uncommonly in follicular-variant PTC, which represents a more favorable variant. However, several series, including ours, emphasized the correlationship between BRAF V600E and the more aggressive clinicopathological outcomes of conventional PTCs, especially in terms of extrathyroid infiltration and advanced stages.2,5 In fact, we confirmed a significant association between BRAF V600E mutation and aggressive histological parameters, such as bilaterality of PTCs (P < .001) and nodal involvement (P < .001), in our PTCs.2
JAMA Oncology , commentaire, 2016